company MBX - SteadyBase

steadybase-$ company MBX

account_id none on file

legal_name MBX Biosciences, Inc.

ticker MBX

cik 1776111

domain mbxbio.com

linkedin_company_url https://www.linkedin.com/company/mbx-biosciences-inc/

entry_point_account_id none on file

name MBX Biosciences Inc.

exchange Nasdaq

sector Health Care

irhttps://investors.mbxbio.com/

sector index/company/sector/health-care/

calls 3 filings 23 executives 4 family 0

why_now

On the OPEX side, we were up 4% on OPEX. Key contributors there were with lower investment income during the year. Again, decline in interest rates led to that. although we did make continued investments in trade shows, as well as increasing our R&D spend, predominantly in the CAPS area, but spending more there.

Dec 18, 2025 / receipt

On the OPEX side, we are continuing to invest in our sales and marketing. We are attending OPEX. We did attend additional trade shows, again, trying to promote both of our businesses. R&D spending is up. Again, we want to make sure that we are investing in new products and launching new products on an ongoing basis.

Aug 14, 2025 / receipt

calls

On the OPEX side, we were up 4% on OPEX. Key contributors there were with lower investment income during the year. Again, decline in interest rates led to that. although we did make continued investments in trade shows, as well as increasing our R&D spend, predominantly in the CAPS area, but spending more there.

Dec 18, 2025 / receipt, needs a key / Jim Curry, CFO | earnings call 2025-12-18 | transcript 2c25867a-f98e-41f1-ace5-b5bc245b6699 | chars 5838-6151 | segment 6

Great question about China. The primary reason that we've seen for the china slowdown a lot of the product that we sell into china is related to respiratory pat testing for respiratory infections and um in asia there's uh you know, for folks that have traveled there, common areas of buildings are typically not heated. There's also a high population density and there is a fair bit of pollution as well. So between Between crowding, you know, pollution and unheated buildings, a lot of times people have a low level respiratory infection. And PCR tests are not really good, are not that quantifiable in the ways they're used there. So they prefer to do immunologic testing, looking for acute phase antibody reactions as really diagnostic as to whether you have an active infection with a clinical impact. And we've been supporting those tests. So there was a lot of what was called white lung or we would call it walking pneumonia in the 2023-2024 season in China.

Aug 14, 2025 / receipt, needs a key / Cameron Groom, CEO | earnings call 2025-08-14 | transcript dafed060-779b-4028-a7b9-4016b9e941b0 | chars 21160-22125 | segment 19

On the OPEX side, we are continuing to invest in our sales and marketing. We are attending OPEX. We did attend additional trade shows, again, trying to promote both of our businesses. R&D spending is up. Again, we want to make sure that we are investing in new products and launching new products on an ongoing basis.

Aug 14, 2025 / receipt, needs a key / Jim Curry, CFO | earnings call 2025-08-14 | transcript dafed060-779b-4028-a7b9-4016b9e941b0 | chars 3763-4080 | segment 3

filings

O n July 9, 2026, the Board appointed John Smither as Chief Financial Officer and principal financial officer and principal accounting officer of the Company, effective as of July 13, 2026.